Article ID Journal Published Year Pages File Type
7281856 Brain, Behavior, and Immunity 2014 6 Pages PDF
Abstract
Natalizumab treatment reduces plasma Osteopontin levels and improves cognition and fatigue in RRMS patients. The results suggest that the improvement of cognitive functions is associated to a decrease of plasma Osteopontin levels.
Keywords
Related Topics
Life Sciences Immunology and Microbiology Immunology
Preview
The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis
Authors
, , , , ,